Charlie Teo Foundation grant to fund key research of new Pharmaxis drug to tackle brain cancer
PXS-5505 will enter pre-clinical efficacy testing for glioblastoma, the most common form of brain cancer with an average survival of only 15 months from diagnosis. Charlie Teo Foundation founder and director Professor Charlie Teo and Pharmaxis CEO Gary Phillips during a TV interview.
Pharmaxis Ltd (ASX:PXS) (FRA:UUD) drug discovery PXS-5505 will be the focus of a new study funded by a grant from the Charlie Teo Foundation, an Australian charity, for key research into a drug discovery tackling an aggressive and deadly form of brain cancer.
Charlie Teo Foundation grant to fund key research of new Pharmaxis Ltd drug to tackle brain cancer proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Architecture news & editorial desk
A new development at Blacktown is set to include a medical research institute (with a university partner), a private hospital, a medi-hotel, retail space, and residential apartments. The project is not only expected to attract millions of dollars in investment but will also create jobs well into the future.
Becoming the site of the Brain and Spinal Institute (BBSI) headed by renowned neurosurgeon Professor Charlie Teo, it will cater for surgeons, patients and their families from Australia and overseas, the BBSI aims to be a world leader in medical research, practice, treatment and recovery.
Facilities at the development include the medical research institute (with a university partner), a private hospital, a medi-hotel, retail space, and residential apartments. The project is not only expected to attract millions of dollars in investment but will also create jobs well into the future.